本发明涉及治疗癌症或其它细胞增殖性疾病的联合治疗。
The present invention is directed to a combinational therapy for treating cancer or other cell proliferative diseases.
慢性粒细胞白血病是一种造血干细胞克隆性增殖所致的骨髓增殖性疾病。
Chronic myelocytic leukemia is a clonal proliferation of hematopoietic stem cells caused by myeloproliferative disorders.
目的：探讨PCR检测基因重排对淋巴细胞恶性增殖性疾病的诊断价值。
Objective: To study the value of detecting the gene rearrangements with PCR in diagnosis of lymphoproliferative diseases.
急性白血病是一种造血系统的恶性增殖性疾病，严重危害人类的生命健康。
Acute leukemia is a kind of hematopoietic system malignant hyperplasia disease, which threaten peoples' lives and health seriously.
所述制剂可有效治疗各种病理病症，包括增殖性疾病、神经障碍和肌骨胳障碍。
The formulation is efficient in treating various pathological conditions, including proliferative diseases, neurological disorders, and musculoskeletal disorders.
本文综述了声动力疗法在肿瘤治疗、血管成形术后再狭窄等增殖性疾病方面的医学应用及相应的生物学机制。
This paper reviews the medical application of sonodynamic therapy in the treatment of tumor and restenosis after percutaneous transcoronary angioplasty and the corresponding biomechanism.
JAK2基因V617F突变在骨髓增殖性疾病中有较高的检出率，可作为骨髓增殖性疾病特异性诊断指标。
There is high frequency of JAK2 V617F mutation in myeloproliferative disorders and it could be used as the diagnostic marker for myeloproliferative disorders.
在BCR- ABL阴性的骨髓增殖性疾病的发病机制中，JAK2V 617 F点突变的发现是一个重大的突破。
In BCR-ABL fusion gene negative myeloproliferative diseases, the discovery of JAK2V617F point mutation is an important landmark.
因此，SHP-2可能是髓系细胞高增殖性信号调控的关键分子，及髓系增殖性疾病的发病机制中重要的调控分子之一。
So SHP-2 could be the key element of the high value-added signal-regulated in myeloid cells and a important regulatory in the pathogenesis of myeloproliferative disorders.
因此，SHP-2可能是髓系细胞高增殖性信号调控的关键分子，及髓系增殖性疾病的发病机制中重要的调控分子之一。
So SHP-2 could be the key element of the high value-added signal-regulated in myeloid cells and a important regulatory in the pathogenesis of myeloproliferative disorders.
应用推荐